Automated Author ProfilePedersen, Jannie
Pedersen, Jannie
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 1.3 (sum of 2 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.
Authors
- Kobinger, Gary P. ;
- Jelinski, Joseph ;
- Kowatsch, Monika M. ;
- Lafrance, Marc-Alexandre ;
- Berger, Alice ;
- Pedersen, Jannie ;
- Azizi, Hiva ;
- Li, Yue ;
- Scholte, Florine ;
- Gomez, Alejandro ;
- Hollett, Natasha ;
- Le, Toby ;
- Wade, Matthew ;
- Fausther-Bovendo, Hugues ;
- de La Vega, Marc-Antoine ;
- Babuadze, George ;
- XIII, Ara ;
- Lamarre, Claude ;
- Racine, Trina ;
- Kang, Chil-Yong ;
- Yao, Xiao-Jian ;
- Alter, Galit ;
- Arts, Eric ;
- Fowke, Keith R.
Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.
Authors
- Jelinski, Joseph ;
- Kowatsch, Monika M. ;
- Lafrance, Marc-Alexandre ;
- Berger, Alice ;
- Pedersen, Jannie ;
- Azizi, Hiva ;
- Li, Yue ;
- Scholte, Florine ;
- Gomez, Alejandro ;
- Hollett, Natasha ;
- Le, Toby ;
- Wade, Matthew ;
- Fausther-Bovendo, Hugues ;
- de La Vega, Marc-Antoine ;
- Babuadze, George ;
- XIII, Ara ;
- Lamarre, Claude ;
- Racine, Trina ;
- Kang, Chil-Yong ;
- Yao, Xiao-Jian ;
- Alter, Galit ;
- Arts, Eric ;
- Fowke, Keith R. ;
- Kobinger, Gary P.